Kalaris Therapeutics Inc. Live Share Price Today, Share Analysis and Chart

Name: Kalaris Therapeutics Inc.: Is Infosys Ltd. worth buying?
Item: Kalaris Therapeutics Inc.
Rating: 1.43650
Author: Trendlyne DVM scores

about

AlloVir Inc is a biopharmaceutical company. The company focuses on developing allogeneic T-cell therapies to combat viral diseases. Their proprietary virus-specific T cell VST therapy platform enables the creation of off-the-shelf VSTs, therapy platf...

2.43 -0.07 (-2.80%)

81.16% Fall from 52W High

68,547

XNAS Volume

XNAS 11 Jul, 2025 5:30 PM (EDT)

Not Eligible

Expensive Valuation

13.5 / 100

Technically Neutral

44.0 / 100

No estimates available

Kalaris Therapeutics Inc. Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Kalaris Therapeutics Inc. Live Share Price Today, Share Analysis and Chart

AlloVir Inc is a biopharmaceutical company. The company focuses on developing allogeneic T-cell therapies to combat viral diseases. Their proprietary virus-specific T cell VST therapy platform enables the creation of off-the-shelf VSTs, therapy platf...

81.16% Fall from 52W High

SWOT Analysis

Kalaris Therapeutics Inc. Live Price Chart